SCHEMBL13086360

SCHEMBL13086360

O=C1O[C@H](c2ccccc2)CN1Cc1cccc(N2CCN(Cc3cccnc3)CC2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.52
GFER P55789 1/20 0.52
POLB P06746 1/20 0.51
TRPV6 Q9H1D0 4/20 0.47
KHK P50053 1/20 0.46
OPRM1 P35372 1/20 0.44
OPRD1 P41143 1/20 0.44
OPRK1 P41145 1/20 0.44
OPRL1 P41146 1/20 0.44
ALDH1A1 P00352 2/20 0.43
TDP1 Q9NUW8 1/20 0.43
DRD2 P14416 2/20 0.41
DRD3 P35462 2/20 0.41
DRD4 P21917 1/20 0.41
FADS1 O60427 1/20 0.41
CASP1 P29466 1/20 0.41
CASP4 P49662 1/20 0.41
CASP5 P51878 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2893160 0.91 MAPT (0.48) KDM4EGFERPOLBTRPV6KHK
SCHEMBL2901778 0.91 DRD2 (0.45) KDM4EGFERPOLBTRPV6KHK
SCHEMBL2901775 0.91 DRD2 (0.45) KDM4EGFERPOLBTRPV6KHK
SCHEMBL2893161 0.91 MAPT (0.48) KDM4EGFERPOLBTRPV6KHK
SCHEMBL2899138 0.88 TRPV6 (0.51) KDM4ETRPV6OPRM1OPRD1OPRK1
SCHEMBL2899137 0.88 TRPV6 (0.51) KDM4ETRPV6OPRM1OPRD1OPRK1
SCHEMBL13086217 0.85 KDM4E (0.45) KDM4EGFERTRPV6OPRM1OPRD1
SCHEMBL2893545 0.82 FADS1 (0.47) DRD2FADS1
SCHEMBL2893548 0.82 FADS1 (0.47) DRD2FADS1
SCHEMBL4328591 0.82 DRD4 (0.54) DRD2DRD3DRD4FADS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US disclosed
US-7816354-B2 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2010-10-19 US disclosed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators NPS PHARMACEUTICALS, INC. (US) 2007-11-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275966-A1 Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM2 KDM4E 3351/4885GFER 833/4885POLB 3048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.